Cohort study of Patients with metastatic colorectal cancer Treated by XELOX with bevacizumab

ABSTRACT: Interventions: 1)Capecitabine at a dose of 2,000mg/m2/day orally in 2 divided doses for 2weeks on and 1week rest 2) tri-Weekly oxaliplatin at a dose of 130mg/m2 intravenously 3) tri-weekly bevacizumab at a dose of 5mg/kg intravenously Primary outcome(s): Frequency and Degree of Hand-foot symdrome(HFS),Neuropathy and Vascular disorders Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2620339 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR